Christopher Marai
Stock Analyst at Nomura
(2.43)
# 2,523
Out of 5,055 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $11.07 | +8,572.09% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $84.61 | -61.00% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $4.24 | +2,022.64% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $449.16 | -83.52% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.94 | +306.61% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $167.55 | +133.96% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $2.09 | +1,526.79% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $18.81 | +1,122.75% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $16.62 | -27.80% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $9.93 | +91.34% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $3.90 | +1,002.56% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $11.07
Upside: +8,572.09%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $84.61
Upside: -61.00%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $4.24
Upside: +2,022.64%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $449.16
Upside: -83.52%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.94
Upside: +306.61%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $167.55
Upside: +133.96%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $2.09
Upside: +1,526.79%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $18.81
Upside: +1,122.75%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $16.62
Upside: -27.80%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $9.93
Upside: +91.34%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $3.90
Upside: +1,002.56%